Canada markets open in 4 hours 3 minutes

Cerus Corporation (CERS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.8000+0.0100 (+0.26%)
At close: 04:00PM EDT
3.8000 0.00 (0.00%)
After hours: 04:01PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • M
    Moscuba
    Too early to tell but seems like we’ve hit market bottom and Cers should follow. MACD crossed but need three days in a row to make that appear semi-solid. Things now are in the Feds hands and Putins. If Putin nukes I wonder if the markets will stop trading world wide and stay closed for days. Gold will soar. I’m not into gold; I have 1Oz I use once a year as a golf ball marker.
  • G
    George
    FYI....

    Cerus Corporation Announces Workshop and Abstracts at the 2022 AABB Annual Meeting
    9/26/2022 8:00:00 AM EDT

    Workshop and Abstracts Highlight the Favorable Impacts Associated with the INTERCEPT Blood System for Platelets and the INTERCEPT Blood System for Cryoprecipitation in Clinical Settings

    CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2022 AABB Annual Meeting, taking place in Orlando, FL from October 1 through October 4. This year’s AABB Annual Meeting attracts individuals and institutions from around the globe involved in the fields of transfusion medicine and biotherapies. This year marks the first time the conference has taken place in person since 2019, as well as its 75th anniversary.

    The following is a select list of presentations and abstracts of interest for Cerus. All presentation times are listed in Eastern Daylight Time (EDT).

    Oral Presentations

    Sunday, October 2, 2022 – 4:30 p.m.– Impact of 100% Pathogen Reduction and 7-Day Storage on Platelet Safety and Availability in France – Plenary Abstract Session
    Monday, October 3, 2022 – 7:00 a.m. – Cerus Industry Workshop
    Poster Presentations

    Held between Sunday, October 2 and Monday, October 3, 2022

    Impact of Pathogen Reduction (PR) vs. LVDS Testing on Platelet Availability: A Study Based on Real-Life Experience
    Comparing Usable Shelf-Life of Pathogen Reduced Platelets vs LVDS Screened Platelets
    Pathogen Reduced Cryoprecipitated Fibrinogen Complex Restores Fibrinogen Levels, Clot Firmness and Thrombin Generation in a Hemodilution Model
    Survival and Growth of Bacteria during Manufacturing and Storage of Cryo-AHF Compared to Pathogen Reduced Cryoprecipitated Fibrinogen Complex
    The full program of Cerus-related abstracts can be found at the following link: https://intercept-usa.com/wp-content/uploads/sites/4/2022/09/2022-AABB-Abstract-Book-FINAL-nocrops.pdf

    Cerus representatives will be in the exhibition area at booth #1108.
  • P
    P
    Cerus awarded DOD contract for $9 mil in IFC
    ( https://sam.gov/opp/f9a513d9578e41718022e470b5149a90/view )
  • G
    George
    Interesting item in the sole sourcing document for CERS CP, #3 from the DOD...

    "3) provide a potential
    manufacturing stream for other medical products that can be lyophilized"

    Any hunches for 'other medical products' ?

    In another Zacks FYI....

    After Plunging 17.6% in 4 Weeks, Here's Why the Trend Might Reverse for Cerus (CERS)
    9/21/2022 10:36:38 AM EDT

    Cerus (CERS) has been beaten down lately with too muchselling pressure. While the stock has lost 17.6% over the past fourweeks, there is light at the end of the tunnel as it is now inoversold territory and Wall Street analysts expect the company toreport better earnings than they predicted earlier.

    How to Determine if a Stock is Oversold

    We use Relative Strength Index (RSI), one of the most commonlyused technical indicators, for spotting whether a stock isoversold. This is a momentum oscillator that measures the speed andchange of price movements.

    RSI oscillates between zero and 100. Usually, a stock isconsidered oversold when its RSI reading falls below 30.

    Technically, every stock oscillates between being overbought andoversold irrespective of the quality of their fundamentals. And thebeauty of RSI is that it helps you quickly and easily check if astock's price is reaching a point of reversal.

    So, by this measure, if a stock has gotten too far below itsfair value just because of unwarranted selling pressure, investorsmay start looking for entry opportunities in the stock forbenefitting from the inevitable rebound.

    However, like every investing tool, RSI has its limitations, andshould not be used alone for making an investment decision.

    Why a Trend Reversal is Due for CERS

    The heavy selling of CERS shares appears to be in the process ofexhausting itself, as indicated by its RSI reading of 29.5. So, thetrend for the stock could reverse soon for reaching the oldequilibrium of supply and demand.

    The RSI value is not the only factor that indicates a potentialturnaround for the stock in the near term. On the fundamental side,there has been strong agreement among the sell-side analystscovering the stock in raising earnings estimates for the currentyear. Over the last 30 days, the consensus EPS estimate for CERShas increased 5.9%. And an upward trend in earnings estimaterevisions usually translates into price appreciation in the nearterm.

    Moreover, CERS currently has a Zacks Rank #2 (Buy), which meansit is in the top 20% of more than the 4,000 stocks that we rankbased on trends in earnings estimate revisions and EPS surprises.This is a more conclusive indication of the stock's potentialturnaround in the near term.

    DOD and Zacks are both trying to tell us something that shorts, hedges and MMs would rather occlude.
  • H
    Hmmm
    fyi...someone (algo/MM) was being cute and ratched the Ask up spoofing with 25k, then 35k, then 45k, then 55k, then 60k shares all within a 1 minute time period around 11:32 AM and someone hit it...the games being played by the MM/algos won't last forever...$600 mil market cap is pretty cheap...it'd be hard to build a company with their IP mote, products, sales, and growth rate selling for 3 times next years sales.

    The intraday volume has been non-existent last week and this week. It continues to be a cat and mouse game, but if the Baker Bros bought last quarter (2Q) in the $4s, I'm sure they'll take what they can get in the $3s as well, with a bunch of the other institutions that like their fundamentals.

    The other thing that should be thought about is if they are adding $30 mil per year in sales with a 50% profit margin and are cash flow positive in 4Q 2022, then they'll be able to start buying back stock soon (2023 if they don't need the cash for an inventory build for the EU RBC launch...if it gets approved). So every year they'll be able to buy back $15 mil more in stock (assuming their growth rate is 15% moving forward).

    Headwinds for the rest of 2022:
    1. tax loss selling
    2. the risk free rate of return (1-5 year treasury rates now range between 4.15% - 4.40%) drawing out market liquidity
    3. market selloff or crash
    please add any other risks to the thread I may have missed
  • M
    Moscuba
    The abstracts are a good read. That's how Cerus increases provider demand; I assume large hospitals that get a lot of trauma patients will find the abstract data compelling. Intercept treated products have a waste percent of around 15% lower waste on average and at least 2 days more useful life for plasma/platelets.
  • h
    hofno2003
    CERS red blood cell product - EU approval next nearterm catalyst - end of this year/early 2023
    ##############################################################################
    Cerus' INTERCEPT red blood cell product (the largest potential market of all with a $5 billion worldwide market) may see approval in Europe late this year (or early next year). If approved in Europe, Cerus could commence a commercial launch of its red blood cell product in Europe in 2023.

    “The INTERCEPT RBC CE Mark submission is a major milestone in the Company’s history and represents the culmination of years of effort to complete the full INTERCEPT portfolio of products to help ensure that patients have access to safe blood transfusions,” said William ‘Obi’ Greenman, the Company’s president and chief executive officer. “Red blood cell transfusions are one of the most common hospital procedures globally, and there are more than 25 million red blood cell units transfused in Europe, Middle East and Africa (EMEA) annually. The INTERCEPT red blood cell system is designed to reduce the risk of transfusion transmitted infections and other potential complications such as transfusion-associated graft-versus host disease.”

    “The INTERCEPT red blood cell system is an important extension to our portfolio and our existing blood center customers are excited about the opportunity to potentially safeguard all three major blood components,” continued Greenman. “We are looking forward to working with the regulatory agencies in EMEA to bring this important product to market.”

    Carol Moore, Cerus’ senior vice president of regulatory affairs and quality, commented, “We anticipate the regulatory review process could exceed 15 months given the breadth of the submission, which covers both device and biologic elements. Our submission will be reviewed by TÜV SÜD, our notified body, and Irish Health Products Regulatory Authority, the competent authority.”
    Source: CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced that it has filed for CE Mark registration for the Company’s INTERCEPT red blood cell (RBC) system. Dec. 2018 (!).

    Actually, the review process may be finished anytime and represents a short term news catalyst (in the next months ahead). Approval given, the rollout in EU should support the revenue topline of 2023 and break-even in operating cash flow and net earnings.
  • C
    Chris
    When will this company be a takeover target?! Owned it for years now.
  • P
    Pippa
    I am staying far away from CERS - It looks like it is going to drop off a cliff. I actually get way better stocks at www.expertinvestor.club
  • M
    Moscuba
    When was the application for 7 day platelet shelf life filed? They didn’t do a press release. It was mentioned in an earnings call. That could get approved soon if that application was in mid 2021 which I think it was. Time gets lost in this boring company and another year of boring to come.
  • M
    Moscuba
    Well, the market will continue to suck for months, at least through the next Fed session. If the increase is .75%: more pain, If .5% the market May relax and stop being all balled up in its underwear. CERS has followed the market on the big swings. Tough stinky poo. I’ve got the stomach on the long term investment.

    Come on 7 day shelf life approval. Come on EU RBC approval.

    Bullish but not short term.
  • M
    Moscuba
    Stock technicals remain in sell/hold but have moved toward buy. After today even closer or maybe into buy. The chart looks good. I’m trading other things and letting CERS to collect dust.
  • j
    jdfich
    Important Update: 2022 AABB Annual Meeting in Orlando is Canceled

    Dear AABB Annual Meeting Attendees and Members of the AABB Community:
    On Monday night, AABB’s Board of Directors made the decision to cancel our upcoming in-person Annual Meeting, scheduled for Oct. 1-4 in Orlando.
    We have all seen the weather reports. Hurricane Ian continues to strengthen and is expected to be an even more powerful storm by the time it reaches Florida later this week. The entire state of Florida is under a state of emergency, with school closures and evacuation orders already being issued.
  • J
    John
    About 3 weeks ago I responded to Moscuba that $4.30 was a given and I thought around $4.00 was likely. Now we are around $4.00 and I think the technicals will prevail for the next 12-18 months (as is commonly posted here..there is not much news coming out for the next 1-2 years). The charts indicate that the next big support is around $3.25 (although I believe the $4.00 support is much stronger if it holds) and I believe the market weakness will dictate how close we get to $3.25. For reasons I won't get in to here (I am not going to make this political and I don't believe either party would make a lot of difference here), I think the chances of getting to $3.25 are pretty good IF we convincingly break $3.90 to the downside. If we get close to $3.50 I will cave and slowly buy more. I think the big risk here is that the ramp up/approval process continues to take a long time (with no certain end in sight) and there may be another product with management that is better equipped to navigate the political oceans will show promise and captures the attention of regulators around the world but until that happens I am a supporter. From what I read, CERS has a good product but management has made mistakes and might not recognize the pitfalls to approval.I expect that the usual suspects will #$%$ all over my opinion (it is still my opinion) but that's fine. The proof is in the historical stock price and the charts.
  • j
    jdfich
    https://aabb.confex.com/aabb/2022/meetingapp.cgi/Home/0

    Search Cerus to get most pertinent abstracts
    2022 Annual Meeting
    aabb.confex.com
  • G
    George
    FYI...

    Down 20.4% in 4 Weeks, Here's Why Cerus (CERS) Looks Ripe for a Turnaround
    8/29/2022 11:20:49 AM EDT

    Cerus (CERS) has been beaten down lately with too muchselling pressure. While the stock has lost 20.4% over the past fourweeks, there is light at the end of the tunnel as it is now inoversold territory and Wall Street analysts expect the company toreport better earnings than they predicted earlier.

    Here is How to Spot Oversold Stocks

    We use Relative Strength Index (RSI), one of the most commonlyused technical indicators, for spotting whether a stock isoversold. This is a momentum oscillator that measures the speed andchange of price movements.

    RSI oscillates between zero and 100. Usually, a stock isconsidered oversold when its RSI reading falls below 30.

    Technically, every stock oscillates between being overbought andoversold irrespective of the quality of their fundamentals. And thebeauty of RSI is that it helps you quickly and easily check if astock's price is reaching a point of reversal.

    So, by this measure, if a stock has gotten too far below itsfair value just because of unwarranted selling pressure, investorsmay start looking for entry opportunities in the stock forbenefitting from the inevitable rebound.

    However, like every investing tool, RSI has its limitations, andshould not be used alone for making an investment decision.

    Why CERS Could Bounce Back Before Long

    The RSI reading of 28.71 for CERS is an indication that theheavy selling could be in the process of exhausting itself, so thestock could bounce back in a quest for reaching the old equilibriumof supply and demand.

    This technical indicator is not the only factor that calls for apotential rebound for the stock. There is a fundamental indicatoras well. A strong agreement among sell-side analysts covering CERSin raising earnings estimates for the current year has led to anincrease in the consensus EPS estimate by 17.6% over the last 30days. And an upward trend in earnings estimate revisions usuallytranslates into price appreciation in the near term.

    Moreover, CERS currently has a Zacks Rank #2 (Buy), which meansit is in the top 20% of more than the 4,000 stocks that we rankbased on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turn around in the near term.
  • M
    Moscuba
    Man, hard not to add my shares back but not adding all the shares has saved me a lot. Back to 2018? Seems headed that way. The trade stream today is 100 or fewer shares. Small hands feed the players because they tend to be weak.
  • C
    Chris
    I’ve been holding this position for 3 yrs. Someone please give me reasons to continue holding it. Thanks
  • P
    P
    Getting well below $4.00 seems unlikely (not impossible). In the last 10 years the stock has only been blasted 2 times. In 2017 when they moved to a new plastic to make the bags for the kits and warned that they might not have enough kits for customers (went below $2) and in 2020 due to the COVID market sell off (went below $3). So 1 Cerus news driven and 1 market driven event tanked the stock.

    The company is close to cash flow break even, no longer needs to dilute shareholders, has the potential for the next 5 years of growth through the IFC product in the US, and has a big wild card with the EU/US RBC product...they seem to be in a good spot.

    Not sure who has been liquidating, but there must be a few institutions flushing positions (ARK has been selling lately and Nikko and Sumitomo Mitsui sold some small amounts in 2Q 2022, Wasatch and Paradigm both cut their holdings by 50% in 2Q and may be exiting to 0%), so this rapid selloff seems like a good place to start nibbling as it stabilizes around $4.00. If it gets into the $3s that seems like it would be a temporary phenomenon due to liquidity (either market or forced institutional selling) or without bad Cerus specific news. No real bounce yet, so we'll see if the sellers have exhausted themselves in the next few days...waiting for confirmation. For now someone is sitting on it, but not willing to sell below $4.00...could also be the MM waiting for all the retail buying to exhaust itself before pushing it down one more time so they can reload before letting the stock run. Definitely some cat and mouse games going on.
  • L
    Len
    Would we accept a buyout price of
    $10 per share from PFE?